Bam

Quote
anonymous said:
I wonder what the floor on the stock price is.

Also wonder how bad it has to get before a big layoff occurs.
Click to expand...
The clues are all around us. One few are talking about is the executive moves in the past year or so. Usually these moves signal to investors a company's priorities in the next decade. In other words, this is where we need to shore up to grow in the future, and we're putting top executives in place who have the right experience to lead it.

So consider that the heir apparent to the CEO has gone from an accomplished scientist/physician and drug developer, to an ex-Abbott finance guy. The R&D portfolio strategy guy, who decides where to place bets, spent his career at McKinsey. He may have the MD credentials, but based on his CV it seems he has never actually practiced medicine, became a consultant after graduating and didn't train.

So knowing what you know about this industry, would this give you confidence as an investor?
 






anonymous said:
Look at history, what happened to other companies that went over patent cliffs without a good pipeline and a real strategy. Lilly is a good example. It took them a looooong time to recognize doubling down on the same thing wouldn’t work anymore. And during that time there was a mass migration of marketing people from Indianapolis to Chicago, enticed by big money to do what they knew. It made us who we are today.
Click to expand...

Well Lilly has always been an industry leader on R&D spend whereas Abbvie is on the lower end.

I don’t think Abbvie has the people, culture, or desire to develop their way out of this.

Which means more desperate mergers I guess.

Ricks successor, if external, is going to cut a massive number of employees and try to go a different direction.
 






anonymous said:
The clues are all around us. One few are talking about is the executive moves in the past year or so. Usually these moves signal to investors a company's priorities in the next decade. In other words, this is where we need to shore up to grow in the future, and we're putting top executives in place who have the right experience to lead it.

So consider that the heir apparent to the CEO has gone from an accomplished scientist/physician and drug developer, to an ex-Abbott finance guy. The R&D portfolio strategy guy, who decides where to place bets, spent his career at McKinsey. He may have the MD credentials, but based on his CV it seems he has never actually practiced medicine, became a consultant after graduating and didn't train.

So knowing what you know about this industry, would this give you confidence as an investor?
Click to expand...

That is very depressing. I mean unless they are excellent at buying other companies and dissecting them for valuable parts. But are they really going to out Pfizer Pfizer?

And the age of patent thickets is over. That’s not a strategy either. And the other big companies all have a par immunology drugs.

So the plan is curing solid tumors? Sure it’s an unmet need. But the FDA requires actual data.
 






anonymous said:
abbvie is known for 3 things:

1. marketing that rivals a consumer products company, just turn on the tv
2. borderline anticompetitive practices that never quite cross the line, but stifle innovation regardless. think patent thickets, very broad non-competes (often enforced), stonewalling competitor clinical trials, etc. it is a very long list
3. dividends

the house of cards created by 1 and 2 is coming down. hard to innovate when you are known for marketing and stifling innovation. but because of 3 i would buy abbv if it goes below 75-ish, because the board will protect dividends at all cost. not good news if you work here, though
Click to expand...

Yeah when your strategy for the stock is “we will fight companies in court” and “you will always get your dividend” it’s pretty hard to get people excited.
 












anonymous said:
That is very depressing. I mean unless they are excellent at buying other companies and dissecting them for valuable parts. But are they really going to out Pfizer Pfizer?

And the age of patent thickets is over. That’s not a strategy either. And the other big companies all have a par immunology drugs.

So the plan is curing solid tumors? Sure it’s an unmet need. But the FDA requires actual data.
Click to expand...
Speaking of dissecting, would you trust a finance guy and consultant to do an organ transplant, or would you rather have a surgeon who knows the human body works and has done it before? But no matter, the finance guy and consultant will have beautiful slides!
 












anonymous said:
Well Lilly has always been an industry leader on R&D spend whereas Abbvie is on the lower end.

I don’t think Abbvie has the people, culture, or desire to develop their way out of this.

Which means more desperate mergers I guess.

Ricks successor, if external, is going to cut a massive number of employees and try to go a different direction.
Click to expand...
A few years ago I interviewed for an asset strategy position in Abbott Park, which is like a time warp machine back to the 70s. At lunch I asked a group of potential coworkers where the labs were, would love to see them... and the answer was we're not really sure where they are.
 






anonymous said:
A few years ago I interviewed for an asset strategy position in Abbott Park, which is like a time warp machine back to the 70s. At lunch I asked a group of potential coworkers where the labs were, would love to see them... and the answer was we're not really sure where they are.
Click to expand...
Four years ago I took a DM job, first phone call with one of the tenured reps went like this.. Love to meet some of your high presrcibers.....rep" so would I"
 






anonymous said:
A few years ago I interviewed for an asset strategy position in Abbott Park, which is like a time warp machine back to the 70s. At lunch I asked a group of potential coworkers where the labs were, would love to see them... and the answer was we're not really sure where they are.
Click to expand...
the only sign that it is not 1976 in AP is the Teslas in the parking lot lol
 












anonymous said:
The only sign that it is not 1976 in AP is the Teslas in the parking lot lol
Click to expand...

Botox cosmetic wasn't around in 1976 so you wouldn't have seen all these grotesque senior citizens with fake faces either. If you're old you're not alone. Embrace your age and stop trying to mask it. Just because you put a Ferrari emblem on a rusted-out piece of shit doesn't mean you have a Ferrari. Just look at the CEO's face, wife, or Bezos's wife. Although, my three (3) examples are more like a Dotson emblem on a Pinto. Scottie's grandpa is calling so I have to go now.
 






anonymous said:
Like a bold non-pussy giving in to utter nonsense? You might be right if you actually knew anything about what you talk about
Click to expand...
People like you are fun to troll. Life must doubly suck, unable to escape the allure of a spray tanned reality TV star, and depending for your livelihood on a Botox'd CEO who has a sweet parachute of his own but will let you go down with the plane.
 






anonymous said:
People like you are fun to troll. Life must doubly suck, unable to escape the allure of a spray tanned reality TV star, and depending for your livelihood on a Botox'd CEO who has a sweet parachute of his own but will let you go down with the plane.
Click to expand...
not just a botoxed ceo, a botoxed ceo with only a high school diploma
 






anonymous said:
Botox cosmetic wasn't around in 1976 so you wouldn't have seen all these grotesque senior citizens with fake faces either. If you're old you're not alone. Embrace your age and stop trying to mask it. Just because you put a Ferrari emblem on a rusted-out piece of shit doesn't mean you have a Ferrari. Just look at the CEO's face, wife, or Bezos's wife. Although, my three (3) examples are more like a Dotson emblem on a Pinto. Scottie's grandpa is calling so I have to go now.
Click to expand...
Now that you mention it, I remember there was a lot of bad plastic surgery roaming the halls. Ran into a former colleague from a previous company, they were barely recognizable.
 






anonymous said:
not just a botoxed ceo, a botoxed ceo with only a high school diploma
Click to expand...

I don’t begrudge him his success. Really not sure why he hasn’t parachuted though. Literally his entire former executive team has.

It’s gonna be what it’s gonna be. Humira is gone. Rinvoq has class warning issues. No new drug launches for awhile.

At some point, finally, all the Abbott poor performers are going to get let go in a huge reorganization.
 


















anonymous said:
Well Lilly has always been an industry leader on R&D spend whereas Abbvie is on the lower end.

I don’t think Abbvie has the people, culture, or desire to develop their way out of this.

Which means more desperate mergers I guess.

Ricks successor, if external, is going to cut a massive number of employees and try to go a different direction.
Click to expand...
I never contemplated an external successor to Rick. Imagine how delightful that could be. Oh to see someone who has a fresh perspective look at the rampant mismanagement of resources and take down all the fiefdoms …it warms my heart just to think of it. How glorious.

This board is such a pick me up. Makes walking the halls on mandatory Tues, Wed, Thurs a little less depressing knowing there are at least few like me.
 






anonymous said:
I never contemplated an external successor to Rick. Imagine how delightful that could be. Oh to see someone who has a fresh perspective look at the rampant mismanagement of resources and take down all the fiefdoms …it warms my heart just to think of it. How glorious.

This board is such a pick me up. Makes walking the halls on mandatory Tues, Wed, Thurs a little less depressing knowing there are at least few like me.
Click to expand...

Your post is ironic since Rick told
Leadership last year that the reason the numbers were down is because people refused to work in person.

that was explanation 1, 2, 3, and 4.

I’m real curious to see what happens by Q4. More biosimilars hit in June.
 






Top Bottom
Back
Quote